Gordon Hyeonjin Bae, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bae’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A150572 · Current
Licensed to practise in California · since 2017 · expires 2027-02-28 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$153,761
Medicare paid this office $153,761 for 869 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 293 | $36,429 | $81 |
| Short return visit (20+ min) | 283 | $19,323 | $53 |
| New patient visit (45+ min) | 112 | $12,011 | $107 |
| Destruction of precancer skin growth, 1 growth | 243 | $11,609 | $37 |
| Destruction of skin growth, 1-14 growths | 165 | $11,551 | $60 |
See all 24 services
| Return visit (30+ min) | 293 | $36,429 | $81 |
| Short return visit (20+ min) | 283 | $19,323 | $53 |
| New patient visit (45+ min) | 112 | $12,011 | $107 |
| Destruction of precancer skin growth, 1 growth | 243 | $11,609 | $37 |
| Destruction of skin growth, 1-14 growths | 165 | $11,551 | $60 |
| New patient visit (30+ min) | 121 | $7,606 | $63 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 39 | $6,334 | $151 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 175 | $4,642 | $26 |
| Destruction of precancer skin growth, 15 or more growths | 35 | $3,290 | $78 |
| Destruction of precancer skin growth, 2-14 growths | 202 | $2,660 | $2 |
| Destruction of skin growth, 15 or more growths | 29 | $2,316 | $68 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.5 cm or less | 14 | $2,089 | $149 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 17 | $1,902 | $112 |
| Biopsy of related skin growth, first growth | 74 | $1,530 | $19 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 36 | $1,334 | $27 |
| Removal of noncancer skin growth of body, arms, or legs, 1.1-2.0 cm | 16 | $1,019 | $54 |
| Removal of noncancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 12 | $1,019 | $73 |
| Punch biopsy, first skin growth | 30 | $1,006 | $34 |
| Injection into skin growth, 1-7 growths | 28 | $982 | $22 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 14 | $830 | $41 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 11 | $509 | $42 |
| Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | 13 | $506 | $39 |
| Punch biopsy, each additional skin growth | 13 | $319 | $21 |
| Biopsy of related skin growth, each additional growth | 12 | $316 | $18 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 12 | More than 66% of doctors who do this |
| Removal of skin lesions | 969 | More than 93% of doctors who do this |
| Removal of tissue | 1-10 | None |
| Removal or shaving of skin growth | 125 | More than 86% of doctors who do this |
| Skin biopsy | 118 | More than 78% of doctors who do this |
Who their Medicare patients are
869 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 14% · Women 51% · Also on Medicaid 20% · Health risk score 1.24. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 64% · Diabetes 24% · Coronary heart disease 22% · Chronic kidney disease 21% · Cancer 17% · Atrial fibrillation 16% · Depression 16% · Heart failure 12% · COPD 10% · Stroke 9% · Dementia 8%.
The office billed $796,267, Medicare allowed $216,712 and paid $153,761; for 4,013 services of 82 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 869 | 4,013 | 75 | 1.24 | $796,267 | $153,761 |
| 2023 | 750 | 3,545 | 75 | 1.32 | $655,900 | $143,268 |
| 2022 | 654 | 2,927 | 75 | 1.25 | $518,554 | $109,702 |
| 2021 | 616 | 2,450 | 74 | 1.17 | $448,824 | $98,929 |
| 2020 | 217 | 888 | 73 | 1.32 | $150,311 | $32,074 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 22 services
| Return visit (30+ min) | 258 | $32,885 | $81 |
| Short return visit (20+ min) | 226 | $16,691 | $55 |
| Destruction of skin growth, 1-14 growths | 146 | $11,697 | $60 |
| Destruction of precancer skin growth, 1 growth | 213 | $10,877 | $39 |
| New patient visit (45+ min) | 87 | $9,960 | $114 |
| New patient visit (30+ min) | 100 | $6,783 | $68 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 38 | $6,128 | $161 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 143 | $3,991 | $27 |
| Destruction of precancer skin growth, 15 or more growths | 36 | $3,418 | $88 |
| Destruction of precancer skin growth, 2-14 growths | 180 | $2,425 | $2 |
| Biopsy of related skin growth, first growth | 89 | $2,102 | $22 |
| Destruction of skin growth, 15 or more growths | 20 | $1,870 | $78 |
| Injection into skin growth, 1-7 growths | 43 | $1,547 | $23 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 13 | $1,537 | $118 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 13 | $1,315 | $88 |
| Removal of noncancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 14 | $993 | $66 |
| Punch biopsy, first skin growth | 28 | $964 | $33 |
| Biopsy of related skin growth, each additional growth | 28 | $915 | $20 |
| Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | 19 | $860 | $43 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 19 | $613 | $27 |
| Short return visit | 13 | $386 | $30 |
| Punch biopsy, each additional skin growth | 13 | $300 | $20 |
2022: 21 services
| Return visit (30+ min) | 193 | $21,966 | $80 |
| Short return visit (20+ min) | 162 | $12,399 | $55 |
| Destruction of precancer skin growth, 1 growth | 166 | $8,200 | $38 |
| New patient visit (45+ min) | 68 | $6,638 | $98 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 249 | $6,590 | $26 |
| Destruction of skin growth, 1-14 growths | 89 | $5,731 | $54 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 33 | $5,053 | $144 |
| New patient visit (30+ min) | 58 | $4,032 | $70 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | 20 | $2,742 | $125 |
| Destruction of precancer skin growth, 15 or more growths | 20 | $2,134 | $82 |
| Biopsy of related skin growth, first growth | 88 | $2,102 | $22 |
| Destruction of precancer skin growth, 2-14 growths | 149 | $1,820 | $2 |
| Punch biopsy, first skin growth | 46 | $1,652 | $33 |
| Removal of noncancer skin growth of body, arms, or legs, 1.1-2.0 cm | 15 | $991 | $55 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 11 | $979 | $82 |
| Punch biopsy, each additional skin growth | 24 | $949 | $22 |
| Destruction of skin growth, 15 or more growths | 12 | $778 | $60 |
| Biopsy of related skin growth, each additional growth | 22 | $737 | $20 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 15 | $736 | $49 |
| Injection into skin growth, 1-7 growths | 20 | $599 | $19 |
| Short return visit | 16 | $463 | $29 |
2021: 18 services
| Return visit (30+ min) | 131 | $16,440 | $84 |
| New patient visit (45+ min) | 109 | $12,510 | $115 |
| Short return visit (20+ min) | 98 | $7,530 | $56 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 267 | $7,331 | $27 |
| New patient visit (30+ min) | 86 | $5,860 | $68 |
| Destruction of precancer skin growth, 1 growth | 126 | $5,769 | $36 |
| Destruction of skin growth, 1-14 growths | 77 | $5,145 | $55 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 27 | $4,001 | $148 |
| Destruction of precancer skin growth, 15 or more growths | 27 | $2,811 | $85 |
| Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm | 11 | $2,170 | $181 |
| Biopsy of related skin growth, first growth | 85 | $1,957 | $21 |
| Punch biopsy, first skin growth | 32 | $1,402 | $39 |
| Destruction of precancer skin growth, 2-14 growths | 108 | $1,391 | $2 |
| Biopsy of related skin growth, each additional growth | 33 | $1,355 | $20 |
| Removal of noncancer skin growth of body, arms, or legs, 1.1-2.0 cm | 11 | $943 | $52 |
| Punch biopsy, each additional skin growth | 18 | $545 | $23 |
| Short return visit | 15 | $450 | $28 |
| Injection into skin growth, 1-7 growths | 16 | $421 | $18 |
2020: 11 services
| Return visit (30+ min) | 83 | $6,561 | $71 |
| New patient visit (30+ min) | 60 | $3,992 | $67 |
| Destruction of precancer skin growth, 1 growth | 69 | $3,545 | $46 |
| Destruction of skin growth, 1-14 growths | 27 | $1,925 | $62 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 56 | $1,769 | $32 |
| Biopsy of related skin growth, first growth | 53 | $1,702 | $27 |
| Destruction of precancer skin growth, 15 or more growths | 15 | $1,698 | $94 |
| Short return visit (20+ min) | 20 | $885 | $40 |
| Biopsy of related skin growth, each additional growth | 21 | $778 | $25 |
| Destruction of precancer skin growth, 2-14 growths | 57 | $710 | $2 |
| New patient visit (15+ min) | 11 | $469 | $43 |
Medicaid work
$61,528 in 2024
Medicaid paid $61,528 for 981 billed services this clinician did in 2024, up to 35 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 292 | $24,609 |
| Short return visit (20+ min) | 200 | $11,251 |
| Service | 203 | $8,446 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 81 | $7,421 |
| New patient visit (30+ min) | 65 | $5,438 |
| TISSUE EXAM BY PATHOLOGIST | 51 | $1,550 |
| New patient visit (45+ min) | 12 | $1,328 |
| Injection, intralesional; up to and including 7 lesions | 12 | $605 |
| Hospital outpatient clinic visit for assessment and management of a patient | 13 | $455 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 52 | $425 |
| 2024 | 981 | 10 | 35 | $61,528 |
| 2023 | 1,406 | 11 | 55 | $53,909 |
| 2022 | 564 | 4 | 43 | $24,692 |
| 2021 | 485 | 5 | 23 | $26,540 |
| 2020 | 106 | 4 | 18 | $5,591 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 431 | $19,397 |
| Service | 298 | $11,781 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 127 | $8,287 |
| Short return visit (20+ min) | 187 | $5,542 |
| New patient visit (45+ min) | 25 | $2,319 |
| New patient visit (30+ min) | 41 | $2,092 |
| TISSUE EXAM BY PATHOLOGIST | 79 | $1,791 |
| Injection, intralesional; up to and including 7 lesions | 101 | $1,403 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 79 | $604 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 12 | $366 |
| Hospital outpatient clinic visit for assessment and management of a patient | 26 | $326 |
2022
| Return visit (30+ min) | 352 | $17,353 |
| Service | 137 | $5,460 |
| Short return visit (20+ min) | 61 | $1,540 |
| TISSUE EXAM BY PATHOLOGIST | 14 | $339 |
2021
| New patient visit (45+ min) | 120 | $10,614 |
| Return visit (30+ min) | 211 | $10,431 |
| Service | 93 | $3,851 |
| Short return visit (20+ min) | 31 | $849 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 30 | $795 |
2020
| Return visit (30+ min) | 52 | $1,997 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 17 | $1,683 |
| New patient visit (30+ min) | 25 | $1,061 |
| Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion | 12 | $850 |
Drugs they prescribed that Part D paid
$615,215
Pharmacies billed $615,215 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
967 generic and 134 brand-name prescriptions · $615,215 in drug cost · 48 antibiotic prescriptions to 38 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 65 | $223,323 | $3,436 |
| Dupixent | 32 | $114,079 | $3,565 |
| Clobetasol Propionate | 87 | $6,111 | $70 |
| Fluocinonide | 66 | $5,626 | $85 |
| Fluorouracil | 38 | $2,924 | $77 |
See all 22 drugs
| Dupixent | 65 | $223,323 | $3,436 |
| Dupixent | 32 | $114,079 | $3,565 |
| Clobetasol Propionate | 87 | $6,111 | $70 |
| Fluocinonide | 66 | $5,626 | $85 |
| Fluorouracil | 38 | $2,924 | $77 |
| Ketoconazole | 114 | $2,603 | $23 |
| Tacrolimus | 21 | $2,372 | $113 |
| Triamcinolone Acetonide | 189 | $1,538 | $8 |
| Ciclopirox | 39 | $1,477 | $38 |
| Mupirocin | 72 | $1,164 | $16 |
| Tretinoin | 17 | $1,114 | $66 |
| Halobetasol Propionate | 13 | $899 | $69 |
| Desonide | 19 | $721 | $38 |
| Clindamycin Phosphate | 18 | $658 | $37 |
| Betamethasone Dipropionate | 11 | $550 | $50 |
| Hydrocortisone | 62 | $524 | $8 |
| Doxycycline Hyclate | 27 | $437 | $16 |
| Minoxidil | 34 | $401 | $12 |
| Valacyclovir | 14 | $324 | $23 |
| Gabapentin | 14 | $233 | $17 |
| Ciclopirox | 12 | $136 | $11 |
| Cephalexin | 18 | $54 | $3 |
Year by year
| 2024 | 1,101 | 373 | None | 12% | $615,215 |
| 2023 | 1,110 | 332 | None | 11% | $610,630 |
| 2022 | 726 | 248 | None | 8% | $270,750 |
| 2021 | 727 | 260 | None | 9% | $145,239 |
| 2020 | 325 | 128 | None | 10% | $115,346 |
| 2019 | 101 | 45 | 0% (0) | 12% | $175,224 |
| 2017 | 89 | 31 | None | 25% | $11,326 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 27 drugs
| Dupixent | 48 | $180,535 | $3,761 |
| Dupixent | 20 | $90,792 | $4,540 |
| Clobetasol Propionate | 99 | $8,577 | $87 |
| Tacrolimus | 33 | $7,631 | $231 |
| Fluocinonide | 66 | $5,602 | $85 |
| Halobetasol Propionate | 29 | $3,324 | $115 |
| Ketoconazole | 96 | $2,807 | $29 |
| Fluorouracil | 29 | $2,631 | $91 |
| Triamcinolone Acetonide | 185 | $2,103 | $11 |
| Desonide | 29 | $1,785 | $62 |
| Ciclopirox | 37 | $1,620 | $44 |
| Hydroxychloroquine Sulfate | 16 | $1,620 | $101 |
| Tretinoin | 15 | $1,485 | $99 |
| Metronidazole | 16 | $1,435 | $90 |
| Betamethasone Dipropionate | 13 | $1,383 | $106 |
| Mupirocin | 52 | $976 | $19 |
| Doxycycline Hyclate | 29 | $894 | $31 |
| Hydroxyzine | 15 | $734 | $49 |
| Valacyclovir | 23 | $642 | $28 |
| Clindamycin Phosphate | 13 | $623 | $48 |
| Hydrocortisone | 42 | $494 | $12 |
| Minoxidil | 15 | $299 | $20 |
| Gabapentin | 16 | $279 | $17 |
| Gentamicin Sulfate | 13 | $245 | $19 |
| Cephalexin | 32 | $173 | $5 |
| Terbinafine | 14 | $146 | $10 |
| Ciclopirox | 12 | $114 | $10 |
2022: 18 drugs
| Dupixent | 19 | $67,917 | $3,575 |
| Clobetasol Propionate | 59 | $8,767 | $149 |
| Fluorouracil | 33 | $3,707 | $112 |
| Fluocinonide | 37 | $3,296 | $89 |
| Ketoconazole | 83 | $3,024 | $36 |
| Tacrolimus | 12 | $1,831 | $153 |
| Desonide | 29 | $1,417 | $49 |
| Ciclopirox | 25 | $1,364 | $55 |
| Tretinoin | 13 | $1,263 | $97 |
| Triamcinolone Acetonide | 111 | $983 | $9 |
| Fluocinolone Acetonide | 11 | $961 | $87 |
| Betamethasone Dipropionate | 13 | $941 | $72 |
| Mupirocin | 34 | $919 | $27 |
| Doxycycline Hyclate | 21 | $716 | $34 |
| Hydroxyzine | 19 | $632 | $33 |
| Hydrocortisone | 33 | $246 | $7 |
| Cephalexin | 33 | $180 | $5 |
| Terbinafine | 12 | $90 | $7 |
2021: 16 drugs
| Dupixent | 17 | $66,813 | $3,930 |
| Fluorouracil | 54 | $5,462 | $101 |
| Clobetasol Propionate | 52 | $4,037 | $78 |
| Betamethasone Dipropionate | 27 | $3,555 | $132 |
| Fluocinonide | 45 | $2,818 | $63 |
| Ketoconazole | 72 | $1,741 | $24 |
| Triamcinolone Acetonide | 103 | $1,726 | $17 |
| Hydroxychloroquine Sulfate | 13 | $1,148 | $88 |
| Tacrolimus | 11 | $1,105 | $100 |
| Ciclopirox | 26 | $714 | $27 |
| Doxycycline Hyclate | 17 | $572 | $34 |
| Hydrocortisone | 60 | $358 | $6 |
| Mupirocin | 24 | $211 | $9 |
| Methotrexate | 11 | $169 | $15 |
| Gabapentin | 23 | $168 | $7 |
| Cephalexin | 32 | $142 | $4 |
2020: 7 drugs
| Clindamycin Phosphate | 15 | $4,611 | $307 |
| Fluocinonide | 41 | $2,652 | $65 |
| Fluorouracil | 14 | $1,413 | $101 |
| Ketoconazole | 37 | $659 | $18 |
| Triamcinolone Acetonide | 38 | $510 | $13 |
| Ciclopirox | 12 | $340 | $28 |
| Hydrocortisone | 27 | $174 | $6 |
2019: 2 drugs
| Fluocinonide | 12 | $701 | $58 |
| Triamcinolone Acetonide | 17 | $229 | $13 |
Money from drug and device companies
$81 in 2024
| 2024 | 1 | 1 | None | $81 |
| 2023 | 1 | 2 | None | $31 |
| 2021 | 2 | 2 | None | $125 |
| 2020 | 1 | 1 | None | $64 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Dupixent | $81 | 1 payment
|
See the published payment
| Regeneron Healthcare Solutions | Education · 2024-09-04 | Dupixent | $81 |
See earlier years (2023, 2021, 2020)
2023: $31
| Pfizer | Cibinqo | $31 | 2 payments
|
2021: $125
| Janssen Biotech | Tremfya | $70 | 1 payment
|
| AbbVie | Skyrizi | $55 | 1 payment
|
2020: $64
| AbbVie | None | $64 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1003265653
- Licence
- CA A150572California A150572: Current · expires 2027-02-28
- Trained
- Harvard Medical School, 2016
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 450 Broadway St, Redwood City, CA, 94063
- NPI first listed
- 2016-06-05
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 75 Francis St, Boston, MA, 02115 · 450 Broadway St, Redwood City, CA, 94063